Trial
NCT03278626
Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
NYU Langone Health
Collaborators
—
Condition
Esophageal Squamous Cell Carcinoma
Intervention
Nivolimumab+Carboplatin/paclitaxel+Radiation
Why stopped
The study was stopped earlier than anticipated due to slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-03-28